A retrospective analysis of cardiovascular outcomes of clozapine treated individuals within Hunter New England
Internal Medicine Journal · 2025
DOI: 10.1111/imj.16617 ↗Kurz gefasst
Fachartikel in der Zeitschrift Internal Medicine Journal, 2025. Verfasst von Shanathan Sritharan und 8 weiteren Autor:innen. Beteiligte Einrichtung: Cardiology Department, John Hunter Hospital Newcastle, Newcastle, New South Wales, Australia. Hauptthemen laut MEDLINE: Clozapine, Antipsychotic Agents, Myocarditis, Schizophrenia, Treatment-Resistant. Die Arbeit wurde bisher 2-mal zitiert (Crossref) und nennt 22 Literaturangaben.
Abstract (Originalsprache)
Background
Clozapine has demonstrated superiority in improving both positive and negative symptoms of treatment‐resistant schizophrenia; however, there are associated treatment‐limiting side effects, including myocarditis, cardiomyopathy and agranulocytosis.
Aim
This retrospective cohort study describes the prevalence of myocarditis, left ventricular (LV) dysfunction, cardiovascular risk factors and outcomes in a cohort of patients maintained on clozapine therapy.
Methods
Data were retrospectively collated from patients who had a diagnosis of schizophrenia, had been managed with clozapine at any stage during their care and undergone at least one echocardiogram.
Results
Between March 2020 and September 2021 674 patients were identified, 71% were male, with a mean age of 47 years old (interquartile range (IQR) 40–57). The mean duration of clozapine use was 7 years (IQR 4–13). The overall mortality was 5.54% during the follow‐up period. Myocarditis was identified in one patient (0.15%) within the first 30 days, and an additional five cases were identified over the follow‐up period (0.89%). The combined incidence of heart failure (HF) and myocarditis was 1.6% during the follow‐up period. There was no association between LV size and function at baseline or during follow‐up and adverse cardiac outcomes (comprising death, myocarditis, HF). Older age at initiation of therapy and baseline E/ e' ratio were associated with risk of HF and myocarditis.
Conclusion
The overall incidence of myocarditis and HF during follow‐up was low, with surveillance echocardiography offering limited predictive value. Patients maintained on clozapine are at risk of significant cardiovascular sequelae, likely reflecting an adverse risk factor profile.
Schlagwörter
MeSH-Schlagwörter (MEDLINE)
Stichwörter der Autor:innen
Substanzen
Autor:innen und Institutionen
- Cardiology Department, John Hunter Hospital Newcastle, Newcastle, New South Wales, Australia.
- School of Medicine and Public Health, University of Newcastle, Newcastle, New South Wales, Australia.
- Hunter Medical Research Institute, Newcastle, New South Wales, Australia.
ORCID-Profile: Shanathan Sritharan
Zitieren
APA
Sritharan, S., Murray, K., Lam, D., Wittaker, D., Sverdlov, A., Boyle, A., Davies, A., Williams, T., & Collins, N. (2025). A retrospective analysis of cardiovascular outcomes of clozapine treated individuals within Hunter New England. Internal Medicine Journal. https://doi.org/10.1111/imj.16617
Vancouver
Sritharan S, Murray K, Lam D, Wittaker D, Sverdlov A, Boyle A, et al. A retrospective analysis of cardiovascular outcomes of clozapine treated individuals within Hunter New England. Internal Medicine Journal. 2025. doi:10.1111/imj.16617
BibTeX
@article{Sritharan2025,
author = {Sritharan, Shanathan and Murray, Kindelan and Lam, Dominic and Wittaker, Daniel and Sverdlov, Aaron and Boyle, Andrew and Davies, Allan and Williams, Trent and Collins, Nicholas},
title = {A retrospective analysis of cardiovascular outcomes of clozapine treated individuals within Hunter New England},
journal = {Internal Medicine Journal},
year = {2025},
doi = {10.1111/imj.16617}
}
EUVIMED